UY25421A1 - VITRONECTIN RECEPTOR ANTAGONISTS - Google Patents
VITRONECTIN RECEPTOR ANTAGONISTSInfo
- Publication number
- UY25421A1 UY25421A1 UY25421A UY25421A UY25421A1 UY 25421 A1 UY25421 A1 UY 25421A1 UY 25421 A UY25421 A UY 25421A UY 25421 A UY25421 A UY 25421A UY 25421 A1 UY25421 A1 UY 25421A1
- Authority
- UY
- Uruguay
- Prior art keywords
- vitronectin receptor
- receptor antagonists
- stenosis
- osteoporosis
- atherosclerosis
- Prior art date
Links
- 102100022337 Integrin alpha-V Human genes 0.000 title abstract 2
- 108010048673 Vitronectin Receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000031481 Pathologic Constriction Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000036262 stenosis Effects 0.000 abstract 1
- 208000037804 stenosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta invención se refiere a compuestos farmacéuticamente activos que inhiben el receptor de vitronectina y son útiles para el tratamiento de inflamación, cáncer y trastornos cardiovasculares, tales como aterosclerosis y estenosis, y enfermedades en las que la resorción ósea es un factor, tal como la osteoporosis.This invention relates to pharmaceutically active compounds that inhibit the vitronectin receptor and are useful for the treatment of inflammation, cancer, and cardiovascular disorders, such as atherosclerosis and stenosis, and diseases in which bone resorption is a factor, such as osteoporosis. .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UY25519A UY25519A1 (en) | 1998-03-10 | 1999-05-19 | PROCEDURE FOR PREPARING VITRONECTIN RECEPTOR ANTAGONIST |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7761098P | 1998-03-10 | 1998-03-10 | |
| US9606398P | 1998-08-11 | 1998-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25421A1 true UY25421A1 (en) | 2001-07-31 |
Family
ID=26759473
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25421A UY25421A1 (en) | 1998-03-10 | 1999-03-10 | VITRONECTIN RECEPTOR ANTAGONISTS |
| UY25519A UY25519A1 (en) | 1998-03-10 | 1999-05-19 | PROCEDURE FOR PREPARING VITRONECTIN RECEPTOR ANTAGONIST |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25519A UY25519A1 (en) | 1998-03-10 | 1999-05-19 | PROCEDURE FOR PREPARING VITRONECTIN RECEPTOR ANTAGONIST |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1061921A4 (en) |
| JP (1) | JP2002506033A (en) |
| KR (1) | KR20010041812A (en) |
| CN (1) | CN1299282A (en) |
| AP (1) | AP2000001898A0 (en) |
| AR (1) | AR015241A1 (en) |
| AU (1) | AU758498B2 (en) |
| BG (1) | BG104824A (en) |
| BR (1) | BR9908636A (en) |
| CA (1) | CA2323208A1 (en) |
| CO (1) | CO5080762A1 (en) |
| DZ (1) | DZ2741A1 (en) |
| EA (1) | EA200000921A1 (en) |
| HU (1) | HUP0101143A3 (en) |
| ID (1) | ID26223A (en) |
| IL (1) | IL138245A0 (en) |
| NO (1) | NO20004503L (en) |
| OA (1) | OA12189A (en) |
| PE (1) | PE20000323A1 (en) |
| PL (1) | PL342881A1 (en) |
| SK (1) | SK13292000A3 (en) |
| TR (1) | TR200002625T2 (en) |
| UY (2) | UY25421A1 (en) |
| WO (1) | WO1999045927A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19939981A1 (en) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | New inhibitors of the integrin alphavß3 |
| DE19939980A1 (en) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitors of the integrin alphavbeta¶3¶ |
| US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| US6448278B2 (en) | 1999-12-23 | 2002-09-10 | Pfizer Inc. | Procollagen C-proteinase inhibitors |
| GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
| FR2808798A1 (en) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | New N-heterocyclyl-aminoacid derivatives and analogs, are vitronectin analogs useful e.g. for treating osteoporosis, tumor growth or metastasis, inflammation or cardiovascular disease |
| PE20020665A1 (en) | 2000-06-15 | 2002-08-14 | Pharmacia Corp | CYCLOALKYL PHENYL ALCANOIC ACID AS ANTAGONIST OF INTEGRINS OVß3 |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6645993B2 (en) | 2001-03-30 | 2003-11-11 | Warner-Lambert Company | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| US20070275956A1 (en) * | 2003-10-14 | 2007-11-29 | Lohray Braj B | Novel Heterocyclic Compounds |
| RU2367661C2 (en) * | 2004-03-05 | 2009-09-20 | Тайсо Фармасьютикал Ко., Лтд. | Thiazole derivatives |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| EP1879864A1 (en) | 2005-04-20 | 2008-01-23 | Janssen Pharmaceutica N.V. | Fluorinated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen containing heteroaryls |
| DK3040329T3 (en) * | 2013-08-29 | 2019-01-28 | Kyoto Pharma Ind | AROMATIC RELATIONSHIP AND APPLICATION THEREOF IN THE TREATMENT OF DISEASES CONNECTED WITH BONE METABOLISM. |
| SI3050878T1 (en) | 2013-09-24 | 2022-01-31 | Fujifilm Corporation | Novel nitrogen-containing compound or salt thereof, or metal complex thereof |
| JP6649902B2 (en) | 2014-05-30 | 2020-02-19 | ファイザー・インク | Carbonitrile derivatives as selective androgen receptor modulators |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000502704A (en) * | 1995-12-29 | 2000-03-07 | スミスクライン・ビーチャム・コーポレイション | Vitronectin receptor antagonist |
| JP2000502708A (en) * | 1995-12-29 | 2000-03-07 | スミスクライン・ビーチャム・コーポレイション | Vitronectin receptor antagonist |
-
1999
- 1999-03-10 AR ARP990101019A patent/AR015241A1/en not_active Application Discontinuation
- 1999-03-10 HU HU0101143A patent/HUP0101143A3/en unknown
- 1999-03-10 BR BR9908636-0A patent/BR9908636A/en not_active Application Discontinuation
- 1999-03-10 IL IL13824599A patent/IL138245A0/en unknown
- 1999-03-10 TR TR2000/02625T patent/TR200002625T2/en unknown
- 1999-03-10 EA EA200000921A patent/EA200000921A1/en unknown
- 1999-03-10 EP EP99909952A patent/EP1061921A4/en not_active Withdrawn
- 1999-03-10 SK SK1329-2000A patent/SK13292000A3/en unknown
- 1999-03-10 AU AU29033/99A patent/AU758498B2/en not_active Ceased
- 1999-03-10 DZ DZ990042A patent/DZ2741A1/en active
- 1999-03-10 AP APAP/P/2000/001898A patent/AP2000001898A0/en unknown
- 1999-03-10 PE PE1999000188A patent/PE20000323A1/en not_active Application Discontinuation
- 1999-03-10 CO CO99014712A patent/CO5080762A1/en unknown
- 1999-03-10 WO PCT/US1999/005232 patent/WO1999045927A1/en not_active Ceased
- 1999-03-10 OA OA00000248A patent/OA12189A/en unknown
- 1999-03-10 PL PL99342881A patent/PL342881A1/en unknown
- 1999-03-10 KR KR1020007010091A patent/KR20010041812A/en not_active Withdrawn
- 1999-03-10 CN CN99805833A patent/CN1299282A/en active Pending
- 1999-03-10 JP JP2000535342A patent/JP2002506033A/en not_active Withdrawn
- 1999-03-10 CA CA002323208A patent/CA2323208A1/en not_active Abandoned
- 1999-03-10 ID IDW20001737A patent/ID26223A/en unknown
- 1999-03-10 UY UY25421A patent/UY25421A1/en unknown
- 1999-05-19 UY UY25519A patent/UY25519A1/en unknown
-
2000
- 2000-09-08 NO NO20004503A patent/NO20004503L/en unknown
- 2000-10-03 BG BG104824A patent/BG104824A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR015241A1 (en) | 2001-04-18 |
| TR200002625T2 (en) | 2000-12-21 |
| UY25519A1 (en) | 1999-12-13 |
| ID26223A (en) | 2000-12-07 |
| OA12189A (en) | 2006-05-09 |
| PE20000323A1 (en) | 2000-05-24 |
| CN1299282A (en) | 2001-06-13 |
| AU2903399A (en) | 1999-09-27 |
| BR9908636A (en) | 2002-01-08 |
| AU758498B2 (en) | 2003-03-20 |
| HUP0101143A3 (en) | 2002-12-28 |
| CO5080762A1 (en) | 2001-09-25 |
| WO1999045927A1 (en) | 1999-09-16 |
| HUP0101143A2 (en) | 2001-08-28 |
| AP2000001898A0 (en) | 2000-09-30 |
| CA2323208A1 (en) | 1999-09-16 |
| SK13292000A3 (en) | 2001-06-11 |
| NO20004503D0 (en) | 2000-09-08 |
| BG104824A (en) | 2001-05-31 |
| EA200000921A1 (en) | 2001-04-23 |
| KR20010041812A (en) | 2001-05-25 |
| DZ2741A1 (en) | 2003-09-08 |
| JP2002506033A (en) | 2002-02-26 |
| PL342881A1 (en) | 2001-07-16 |
| IL138245A0 (en) | 2001-10-31 |
| EP1061921A1 (en) | 2000-12-27 |
| NO20004503L (en) | 2000-10-10 |
| EP1061921A4 (en) | 2005-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25421A1 (en) | VITRONECTIN RECEPTOR ANTAGONISTS | |
| AR010873A1 (en) | VITRONECTIN RECEPTOR ANTAGONIST COMPOUNDS, INTERMEDIARIES, METHODS OF THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES. | |
| AR005987A1 (en) | COMBINED THERAPY FOR OSTEOPOROSIS | |
| ES2134859T3 (en) | DERIVATIVES OF 4-CARBOXOAMIDO-PIPERIDINE, INTERMEDIATE PRODUCTS AND USE AS NEUROKININE ANTAGONISTS. | |
| GT199900070A (en) | DERIVATIVES OF ISOTIAZOLE, USEFUL AS ANTI-CANCER AGENTS. | |
| ES2194223T3 (en) | INTEGRINE ANTAGONISTS. | |
| PA8452701A1 (en) | PROSTAGLANDIN AGONISTS | |
| ES2074736T3 (en) | PROCEDURE FOR THE PRODUCTION OF POLYFLUOROOLEFINS. | |
| ATE294163T1 (en) | INTEGRIN RECEPTOR ANTAGONISTS | |
| GT199800158AA (en) | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | |
| DK1040111T3 (en) | Integrin receptor antagonists | |
| CR7048A (en) | MATRIX METALOPROTEINAS PYRIDINE INHIBITORS | |
| DE69830806D1 (en) | INTEGRIN RECEPTOR ANTAGONISTS | |
| BR0310087A (en) | Hyaluronic acid injectable solid carriers for application of osteogenic proteins | |
| BR0105457A (en) | Therapeutic combinations to stimulate bone growth | |
| CO5611124A2 (en) | BENZOFURAN DERIVATIVES SUBSTITUTED USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | |
| HN2002000365A (en) | LACTAMAS AS TAQUIQUININE ANTAGONISTS | |
| ATE281432T1 (en) | C-16 UNSATURATED FP-SELECTIVE PROSTAGLANDIN ANALOGUE | |
| UY25824A1 (en) | VITRONECTIN RECEPTOR ANTAGONIST | |
| DK1638544T3 (en) | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | |
| BR0015781A (en) | Pharmaceutical composition for treatment of diseases associated with decreased bone mass | |
| GT199900083A (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY. | |
| AR042065A1 (en) | A METHOD FOR PREPARING INDANO-1,3-DICARBOXYL ACID | |
| DK1756046T3 (en) | Arylalkylsulfonamides as therapeutic agents for the treatment of bone disorders | |
| UY26651A1 (en) | COMBINED THERAPY FOR OSTEOPOROSIS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ABAN | Application deemed to be withdrawn (no publication fee paid) |
Effective date: 20090715 |